home | publications

2004 PUBLICATIONS

1. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.
Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS.
Int J Oncol. 2004 Oct;25(4):1057-64.
Abstract

2. Elevated expression of PCGEM1, a prostate-specific gene with cell growth promoting function, is associated with high-risk prostate cancer patients.
Petrovics G, Zhang W, Makarem M, Street JP, Connelly RR, Sun L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S.
Oncogene, 23:605-611, 2004.
Abstract

3. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working group.
Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, and Soule HR:
J Clin Oncol, 22(3):537-56, 2004.
Abstract

4. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O’Reilly K, Hernandez J, Chung A, Soderdahl D:
J Urol, 171:1141-47, 2004.
Abstract

5. Race/Ethnicity and the intensity of medical monitoring under “watchful waiting” for prostate cancer.
Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis WW, Moul JW, Fahey A:
Medical Care, 42:239-50, 2004.
Abstract

6. Race/Ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
Shavers VL, Brown M, Potosky AL, Klabunde CN, Davis WW, Moul JW, Fahey A:
J Gen Intern Med, 19:146-55, 2004.
Abstract

7. External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence.
Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith CV, Connelly RR, McLeod DG, Moul JW:
PCPD, 7:170-177, 2004.
Abstract

8. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D’Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH:
J Natl Cancer Inst, 96:509-15, 2004.
Abstract

9. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
Penson David F, Moul Judd W, Evans Christopher P, Doyle John J [S], Gandhi Sanjay, Lamerato Lois:
J Urol, 171(6, Part 1 of 2):2250-2254, 2004.
Abstract

10. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR:
J Urol, 166:1322-1327, 2001.

11. Watchful Waiting and Factors Predictive of Secondary Treatment of Localized Prostate Cancer.
Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D.
J Urol, Vol 171(3) March 2004 pp 1111-1116
Abstract

12. Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy.
Moul JW et al:
J Urol, Vol 171(3) March 2004 pp 1141-1147
Abstract

13. PSA-based biomarker for predicting mortality in prostate cancer.
Moul JW et al:
Am J of Urol Rev, 2(6):271-277, 2004.

14.Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy.
Amling, Christopher L.; Riffenburgh, Robert H.; Sun, Leon; Moul, Judd W.; Lance, Raymond S.; Kusuda, Leo; Sexton, Wade J.; Soderdahl, Douglas W.; Donahue, Timothy F.; Foley, John P.; Chung, Andrew K.; McLeod, David G.:
Jour of Clin Oncology, Vol 22(3) 1 February 2004 pp 439-445
Abstract

15. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z.
Dis Markers. 2003-2004;19(4-5):185-95.
Abstract